Phase II
It was a moderately busy week for clinical trial news. Here’s a look.
Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.
Amgen presented positive topline data from the Phase II CodebreaK 100 trial of sotorasib in KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC).
New long-term safety and efficacy data highlights the medication’s capabilities in allowing patients to maintain fewer migraine days over a period of five years.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
The trial was initially placed on hold in November 2019 due to safety concerns.
Although still preliminary, Regeneron Pharmaceuticals announced early data from its Phase I/II/III trial of its antibody cocktail, REGN-COV2, against COVID-19.
The importance of diversity of patients in clinical studies cannot be overlooked, nor can the importance of diversity at the C-suite level. But, it’s equally important to have a diverse clinical research team as well.
Pennsylvania-based Inovio said the regulatory agency has additional questions about the Phase II/III trial regarding the vaccine candidate itself, known as INO-4800, as well as the company’s Cellectra 2000 delivery device.
PRESS RELEASES